Kyle Bass Doubles Down: New IPR Petitions Filed

Posted by Tom Chlebeck on Aug 21, 2015

Yesterday, Kyle Bass and his hedge funds opened a new front in their war against patent owners (on which we have reported previously) by filing three new IPR petitions. This time, the Bass Coalition has attacked U.S. Patent Nos. 7,582,621 (IPR2015-01776) and 7,767,657 (IPR2015-01780 and IPR2015-01785). Assigned to Anacor Pharmaceuticals, Inc., these patents cover KERYDIN® (tavaborole), which is an antifungal medication approved by the FDA for treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

On the same day in related IPR proceedings, Celgene responded to the Coalition’s defense of this unusual market manipulation strategy (see, for example, IPR2015-01103 Paper 19).

The saga continues. Stay tuned as we follow the latest developments.

Topics: Kyle Bass

Wolf Greenfield's Post-Grant Blog

Here, the Post-Grant Proceedings Group
at Wolf Greenfield keeps you up to date
on the latest decisions and best practices, and what they mean for you. Learn more about the group and its members.

New Call-to-action
New Call-to-action
New Call-to-action

Subscribe to Email Updates

Recent Posts

Follow Us

This blog is intended to promote thought and debate on developing areas of the law. The opinions, commentary and characterizations of cases provided on this blog are not legal advice and do not represent the opinions of Wolf Greenfield or its clients.